Juan Du

30PUBLICATIONS
103CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 26, 2026
Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.

|Jun 18, 2026
Anti-CD19 CAR-T in transformed indolent lymphoma versus de novo large B-cell lymphoma: a meta-analysis of 5,006 patients.

|Apr 02, 2026
BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

Jin Liu, Xiaoqiang Fan, Liying Peng

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Feb 21, 2026
Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.

Zhiqiang Song, Qingcheng Fu, Juan Du

|Feb 14, 2026
Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapies.

Haiyan He, Qingcheng Fu, Xuerou Yu

Pageof 5

Frequent Collaborators

3 joint publications

Yang Liang

3 joint publications

Juan Li

3 joint publications

Zhi Cheng

2 joint publications

Xiaoxia Hu